Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Palandri F, Breccia M, Mazzoni C, Auteri G, et al. Cancer 2023;129:1704-1713.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Palandri F, Breccia M, Mazzoni C, Auteri G, et al. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer 2023;129:1704-1713.
PMID: 36932983